Does proton pump inhibitor reduce the antiaggregant efficacy of aspirin in ischemic stroke?

Acta Neurol Taiwan. 2023 Mar 30:32(1):9-15.

Abstract

Objective: To evaluate the effect of using acetylsalicylic acid (aspirin) together with lansoprazole in the secondary prevention of ischemic stroke.

Materials and methods: 199 patients with a diagnosis of ischemic stroke and transient ischemic attack (TIA) using 100 mg aspirin regularly were included in the study. All patients were evaluated for the presence of aspirin resistance before starting the study. 57 patients with aspirin resistance were excluded from the study. The remaining 142 patients were divided into two groups: the 1st group consisted of those with stomach discomfort and the 2nd group consisted of those without stomach discomfort. Patients in group 1 were given 30 mg of lansoprazole taken before breakfast in addition to aspirin therapy. All patients were re-evaluated for the presence of aspirin resistance at a one-month follow-up. The antiaggregant activity was evaluated by the impedance aggregometry method in both groups.

Results: Of 142 patients, 75 were in group 1, and 67 were in group 2. There was no difference between the two groups in terms of age and gender distribution of vascular risk factors. There was no statistically significant difference between the two groups in terms of aspirin efficacy. The dose of aspirin was increased in patients with aspirin resistance (AR).

Conclusion: The combination of 30 mg lansoprazole and 100 mg aspirin does not cause a decrease in antiaggregant activity in the early period, but chronic use was not evaluated in this study. Patients with AR may benefit from an increase in the dose of aspirin.

Keywords: Aspirin; aspirin resistance; ischemic stroke transient global amnesia.; proton pump inhibitors.

MeSH terms

  • Aspirin / pharmacology
  • Aspirin / therapeutic use
  • Humans
  • Ischemic Stroke*
  • Proton Pump Inhibitors* / pharmacology
  • Proton Pump Inhibitors* / therapeutic use

Substances

  • Aspirin
  • Proton Pump Inhibitors